文献速递白血病

CRLF2在成人Ph阴性急性B淋巴细胞白血病中的表达及其预后意义

[The expression of CRLF2 in adult Ph negative acute B lymphocytic leukemia and its prognostic significance].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2018-01-01

研究检测了103例初诊成人Ph阴性B-ALL患者骨髓白血病细胞CRLF2表达,以20%为界分为高表达组和低表达组。高表达组中位OS和DFS均短于低表达组,多因素分析显示CRLF2高表达是OS和DFS的独立危险因素。

要点

  • CRLF2高表达组中位OS 9.0个月、DFS 4.25个月,低表达组分别为15.5个月和10.25个月。
  • CRLF2高表达是OS的独立危险因素(HR=2.991,95%CI 1.429~6.261,P=0.004)。
  • CRLF2高表达是DFS的独立危险因素(HR=2.374,95%CI 1.146~4.960,P=0.041)。

核心结论

  • 合并CRLF2高表达的成人初治B-ALL患者预后不良。

研究设计与样本

  • 收集郑州大学附属肿瘤医院血液科2016年4月1日至2017年12月31日收治的103例初治成人B-ALL患者骨髓标本。
  • 应用流式细胞术CD45/SSC设门检测原始细胞CRLF2表达率。
  • 将CRLF2表达率≥20%定义为高表达组,<20%定义为低表达组,比较两组临床特征及预后差异。

主要发现

  • CRLF2高表达组中位OS为9.0个月,CRLF2低表达组为15.5个月,差异有统计学意义(P=0.007)。
  • CRLF2高表达组中位DFS为4.25个月,CRLF2低表达组为10.25个月,差异有统计学意义(P=0.000)。
  • CRLF2高表达组18个月OS率为38.6%,CRLF2低表达组为57.8%,差异有统计学意义(P=0.047)。
  • CRLF2高表达组18个月DFS率为25.1%,CRLF2低表达组为42.3%,差异有统计学意义(P=0.016)。
  • 多因素分析显示CRLF2高表达是影响OS(HR=2.991,95%CI 1.429~6.261,P=0.004)和DFS(HR=2.374,95%CI 1.146~4.960,P=0.041)的独立危险因素。

关键数值与推荐

  • CRLF2表达率≥20%定义为高表达组,<20%定义为低表达组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To detect the expression of CRLF2 in adult Ph negative acute B lymphocytic leukemia (B-ALL) in newly diagnosed cases, and to investigate the relationship between CRLF2 and the general clinical characteristics, efficacy and prognosis. Methods: 103 cases of newly diagnosed adult B-ALL patients were investigated from Apr 2016 to Dec 2017 in the Department of Hematology, Henan Cancer Hospital. Bone marrow samples was used to detect the expression of CRLF2 in leukemic cells. The expression of CRLF2 ≥20% was defined as CRLF2-high group and <20% was defined as CRLF2-low group. The clinical characteristics and prognosis of the two groups were compared. Results: The Median overall survival (OS) and disease free survial (DFS) in CRLF2-high group were 9.0 months and 4.25 months, respectively. CRLF2-low group were 15.5 months and 10.25 months, respectively. There was a statistically significant difference in median OS and DFS between the two groups (P=0.007, P=0.000) . The 18-month OS and DFS in CRLF2-high group were 38.6% and 25.1%, respectively. CRLF2-low group were 57.8% and 42.3%, respectively. Multivariate analysis showed high expression of CRLF2 was an independent risk factor for OS (HR=2.991, 95% CI 1.429-6.261, P=0.004) and DFS (HR=2.374, 95%CI 1.146-4.960, P=0.041) in patients. Conclusion: Patients with high expression of CRLF2 had poor prognosis. 目的: 检测CRLF2蛋白在初诊成人非Ph阳性急性B淋巴细胞白血病(B-ALL)中的表达情况,探讨CRLF2蛋白的表达与患者临床特征、疗效及预后的关系。 方法: 收集郑州大学附属肿瘤医院血液科2016年4月1日至2017年12月31日收治的103例初治成人B-ALL患者骨髓标本,应用流式细胞术CD45/SSC设门检测原始细胞CRLF2表达率,将CRLF2表达率≥20%定义为高表达组,<20%定义为低表达组,比较两组患者的临床特征及预后差异。 结果: CRLF2高表达组中位总生存(OS)、无病生存(DFS)时间分别为9.0和4.25个月,CRLF2低表达组分别为15.5和10.25个月,差异有统计学意义(P值分别为0.007、0.000)。CRLF2高表达组18个月OS率、DFS率分别为38.6%和25.1%,CRLF2低表达组分别为57.8%和42.3%,差异有统计学意义(P值分别为0.047、0.016)。多因素分析显示CRLF2高表达是影响患者OS(HR=2.991,95%CI 1.429~6.261,P=0.004)和DFS(HR=2.374,95%CI 1.146~4.960,P=0.041)的独立危险因素。 结论: 合并CRLF2高表达的成人初治B-ALL患者预后不良。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Chen H, Wang XJ, Liu S, et al. [The expression of CRLF2 in adult Ph negative acute B lymphocytic leukemia and its prognostic significance]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 30369203. doi:10.3760/cma.j.issn.0253-2727.2018.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。